All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
In newly diagnosed multiple myeloma (NDMM), renal impairment is a well-established risk factor leading to lower overall survival (OS) rates. Renal impairment is a modifiable risk factor and can be overcome with intensive therapy.
Using data from the CALM (Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma) study database (42206644), Christoph Scheid, University of Cologne, Cologne, DE, and colleagues retrospectively analyzed the impact of renal function at diagnosis and at transplant, in patients with MM undergoing stem cell transplant. The results were presented during the 45th Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Frankfurt, Germany, on Wednesday 27 March 2019. The study was on behalf of the EBMT chronic malignancies working party (CMWP).1
Table 1: Patient characteristics by GFR at diagnosis
Factor |
GFR ≥50 |
GFR 30–50 |
GFR <30 |
P |
---|---|---|---|---|
Age |
58 (22–75) |
60 (25–74) |
59 (27–76) |
0.045 |
Male vs female |
59% vs 41% |
64% vs 36% |
60% vs 40% |
0.36 |
ISS stage (I vs II vs III) |
45% vs 38% vs 12% |
10% vs 37% vs 47% |
6% vs 16% vs 71% |
<0.001 |
Karnofsky performance (<90% vs ≥90%) |
29% vs 71% |
29% vs 71% |
40% vs 60% |
0.007 |
≥ VGPR vs other |
45% vs 55% |
52% vs 48% |
50% vs 50% |
0.006 |
CD34+ cells |
3.86 x 106 /kg |
3.87 x 106 /kg |
4.15 x 106 /kg |
0.66 |
GFR ≥50 at transplant |
98% |
79% |
49% |
<0.001 |
Melphalan 200mg/m2 vs other |
55% vs 45% |
52% vs 48% |
37% vs 63% |
<0.001 |
GFR, glomerular filtration rate; ISS, International Staging System; VGPR, very good partial response |
Table 2: Renal function at diagnosis versus transplant by GFR rate
At diagnosis |
N |
At transplant |
N |
---|---|---|---|
GFR ≥50 |
1408 |
GFR ≥50 |
1654 |
GFR 30–50 |
180 |
GFR 30–50 |
121 |
GFR <30 |
268 |
GFR <30 |
81 |
GFR, glomerular filtration rate |
Looking at the relationship between renal function at diagnosis and transplant and OS, progression-free survival (PFS), non-relapse mortality (NRM) and relapse incidence (Table 3), it is possible to conclude that:
Patients with a poor renal function at diagnosis had better outcomes (OS and PFS) if they maintained their poor status at transplant, compared with those who improved their renal performance between diagnosis and transplant.
Table 3: Associations between OS, PFS, NRM, relapse incidence and renal function at diagnosis and transplant
Factor |
Renal function at diagnosis: P value |
Renal function at transplant: P value |
---|---|---|
OS |
< 0.001 |
0.1 |
PFS |
0.8 |
0.003 |
NRM |
0.99 |
0.33 |
Relapse incidence |
0.74 |
0.0012 |
NRM, ; PFS, progression free survival; OS, overall survival |
In order to explain these findings, a multivariate analysis (Cox model) was conducted (Table 4). These results are clear, statistically, but difficult to interpret.
Table 4: Multivariate analysis of OS
GFR, glomerular filtration rate; ISS, international Staging System; PR, partial response | ||
Factor |
Hazard ratio |
P value |
---|---|---|
GFR 30–50 at diagnosis |
1.12 |
0.22 |
GFR <30 at diagnosis |
2.2 |
< 0.0001 |
GFR 30–50 at transplant |
0.48 |
0.00034 |
GFR <30 at transplant |
0.25 |
< 0.0001 |
ISS stage II |
1.22 |
0.053 |
ISS stage III |
1.49 |
0.0028 |
Age |
1.01 |
0.10 |
Response < PR at transplant |
1.96 |
< 0.0001 |
Karnofsky 90–100% |
0.82 |
0.038 |
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?